Runda Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Runda Xu has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Xun Lan
Tsinghua University
26 shared publications - Xin Lin
Institute for Immunology and School of Basic Medical Sciences, Tsinghua University, Beijing, China
24 shared publications - Chang Liu
Tsinghua University
22 shared publications - Chen Tian
Tsinghua University-Peking University Joint Center for Life Sciences, Tsinghua University, Beijing, China
22 shared publications - Chunhua Lin
Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University
22 shared publications - Hao Yuan
Department of Basic Medical Sciences, Tsinghua University School of Medicine, Beijing, China
22 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (11) , 5601
Author Correction: Tracking-seq: a universal off-target detection approach for CRISPR–Cas genome editing
- 22 September 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (11) , 5601
Open AccessAuthor Correction: Tracking-seq: a universal off-target detection approach for CRISPR–Cas genome editing
- Open Access
- 11 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9659
Ultra-sensitive profiling of CRISPR-Cas off-target effects with Tracking-seq2
Accurate detection of off-target activity in primary human cells is crucial for ensuring the safety of gene therapies, yet existing methods often lack sufficient sensitivity. To address this limitation, we develop Tracking-seq2, an advanced technology that integrates exogenous 5′ → 3′ exonuclease treatment and non-homologous end joining (NHEJ) pathway inhibitors with the original Tracking-seq. Tracking-seq2 exhibits enhanced sensitivity in profiling off-target sites of diverse genome editors—including Cas9, Cas12a, cytosine base editors (CBEs), adenine base editors (ABEs), and prime editors (PEs). Critically, Tracking-seq2 is directly applicable to clinically relevant primary human cell types, such as T cells and CD34 + hematopoietic stem and progenitor cells (HSPCs). Furthermore, our findings reveal that genomic variations drive distinct off-target heterogeneity across different individuals, highlighting the necessity for personalized safety assessment in clinical genome editing applications. Tracking-seq2 provides a robust platform for sensitive off-target detection in primary cells, with sensitivity comparable to or exceeding current state-of-the-art methods.
- 11 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 9659
Open AccessUltra-sensitive profiling of CRISPR-Cas off-target effects with Tracking-seq2
Accurate detection of off-target activity in primary human cells is crucial for ensuring the safety of gene therapies, yet existing methods often lack sufficient sensitivity. To address this limitation, we develop Tracking-seq2, an advanced technology that integrates exogenous 5′ → 3′ exonuclease treatment and non-homologous end joining (NHEJ) pathway inhibitors with the original Tracking-seq. Tracking-seq2 exhibits enhanced sensitivity in profiling off-target sites of diverse genome editors—including Cas9, Cas12a, cytosine base editors (CBEs), adenine base editors (ABEs), and prime editors (PEs). Critically, Tracking-seq2 is directly applicable to clinically relevant primary human cell types, such as T cells and CD34 + hematopoietic stem and progenitor cells (HSPCs). Furthermore, our findings reveal that genomic variations drive distinct off-target heterogeneity across different individuals, highlighting the necessity for personalized safety assessment in clinical genome editing applications. Tracking-seq2 provides a robust platform for sensitive off-target detection in primary cells, with sensitivity comparable to or exceeding current state-of-the-art methods.
- 24 March 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (9) , 4169-4191
Tracking-seq: a universal off-target detection approach for CRISPR–Cas genome editing
Tracking-seq is a highly sensitive method for genome-wide detection of off-target effects in cells edited with diverse genome editing modalities, including Cas9, cytosine base editors, adenine base editors and prime editors. Since most genome editors induce DNA repair pathways and generate single-stranded DNA (ssDNA) intermediates, Tracking-seq leverages this process by tracking replication protein A-a key protein that binds and protects ssDNA-to identify on-target and off-target events. Here we provide a detailed protocol for Tracking-seq, covering genome editing of cells, extraction of replication protein A-bound ssDNA, sequencing library construction and data analysis using our custom computational tool Offtracker. Tracking-seq is applicable to various genome editing scenarios with low cell input, delivering high-performance results. The entire workflow, from genome editing to data analysis, can be completed within 1-2 weeks, making it a rapid solution for assessing genome-wide off-target activity.
- 24 March 2026
- Published by Springer Nature in Nature Protocols
- Vol. 21 (9) , 4169-4191
Tracking-seq: a universal off-target detection approach for CRISPR–Cas genome editing
Tracking-seq is a highly sensitive method for genome-wide detection of off-target effects in cells edited with diverse genome editing modalities, including Cas9, cytosine base editors, adenine base editors and prime editors. Since most genome editors induce DNA repair pathways and generate single-stranded DNA (ssDNA) intermediates, Tracking-seq leverages this process by tracking replication protein A-a key protein that binds and protects ssDNA-to identify on-target and off-target events. Here we provide a detailed protocol for Tracking-seq, covering genome editing of cells, extraction of replication protein A-bound ssDNA, sequencing library construction and data analysis using our custom computational tool Offtracker. Tracking-seq is applicable to various genome editing scenarios with low cell input, delivering high-performance results. The entire workflow, from genome editing to data analysis, can be completed within 1-2 weeks, making it a rapid solution for assessing genome-wide off-target activity.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.2. EGFR driven lung adenocarcinoma resembles a “cold” TME, Related to Figure 1 (A) Gating strategy for living cells in a single cell suspension prepared from a lung tumor, after excluding erythrocytes. (B) Heatmap showing the expression patterns of the top 10 ranked marker genes for each cell type. (C) Bar plot quantifying the proportions of various types of non-immune or immune cells at each time point from the two biological replicates, highlighting the high repeatability of each cell type compositions in the two experiments. (D) The ratio of fibroblasts, lymphatic endothelial cells, endothelial cells, epithelial cells in each induced time point from the two biological replicates, highlighting the high repeatability of each cell type compositions in the two experiments. The dashed line indicates replicate1, Solid line indicates replicate 2. (E-F) Flow cytometry analysis of lung cell suspensions derived from doxycycline-induced mice (2mg/ml) for 0, 1, 2, and 4 weeks. (E) Flow cytometry plots of epithelial cells (CD45-CD326+) (top) and macrophages (CD45+Ly6G-CD64+) and neutrophils (CD45+Ly6G+) (bottom). (F) Flow cytometry frequencies of neutrophils (CD45+Ly6G+) (top left), monocytes (CD45+Ly6G-MHCII-CD64-CD11C-Siglecf-CD11b+Ly6C+) (top right), B cells (CD45+CD19+) (bottom left), and T cells (CD45+CD3+) (bottom right) at the indicated time points. Each dot represents an individual mouse. (G) Flow cytometry analysis of the absolute number of B cells (CD45⁺CD19⁺, top) and T cells (CD45⁺CD3⁺, bottom) in lung tissue from doxycycline-induced mice (2 mg/mL) at 0, 4, and 8 weeks. Cell counts are shown per milligram of lung tissue, representing cell density-normalized absolute numbers.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.2. EGFR driven lung adenocarcinoma resembles a “cold” TME, Related to Figure 1 (A) Gating strategy for living cells in a single cell suspension prepared from a lung tumor, after excluding erythrocytes. (B) Heatmap showing the expression patterns of the top 10 ranked marker genes for each cell type. (C) Bar plot quantifying the proportions of various types of non-immune or immune cells at each time point from the two biological replicates, highlighting the high repeatability of each cell type compositions in the two experiments. (D) The ratio of fibroblasts, lymphatic endothelial cells, endothelial cells, epithelial cells in each induced time point from the two biological replicates, highlighting the high repeatability of each cell type compositions in the two experiments. The dashed line indicates replicate1, Solid line indicates replicate 2. (E-F) Flow cytometry analysis of lung cell suspensions derived from doxycycline-induced mice (2mg/ml) for 0, 1, 2, and 4 weeks. (E) Flow cytometry plots of epithelial cells (CD45-CD326+) (top) and macrophages (CD45+Ly6G-CD64+) and neutrophils (CD45+Ly6G+) (bottom). (F) Flow cytometry frequencies of neutrophils (CD45+Ly6G+) (top left), monocytes (CD45+Ly6G-MHCII-CD64-CD11C-Siglecf-CD11b+Ly6C+) (top right), B cells (CD45+CD19+) (bottom left), and T cells (CD45+CD3+) (bottom right) at the indicated time points. Each dot represents an individual mouse. (G) Flow cytometry analysis of the absolute number of B cells (CD45⁺CD19⁺, top) and T cells (CD45⁺CD3⁺, bottom) in lung tissue from doxycycline-induced mice (2 mg/mL) at 0, 4, and 8 weeks. Cell counts are shown per milligram of lung tissue, representing cell density-normalized absolute numbers.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.7 Inhibition of the BMP2/4-ACVR1 axis reverses macrophage polarization, related to Figure 5 (A) The expression of representative marker genes superimposed on the t-SNE plots. Each color indicates a subtype of alveolar macrophages. (B) Heatmap showing the expression pattern of the top 10 marker genes for each subtype of alveolar macrophages, determined using Seurat. (C) Depiction of a network for ligand-receptor interactions (LRIs) among different cell types in mouse lungs treated with DOX+LDN. Each node represents a cell type. The size of each node shows the number of LRIs occurring for each given cell type. The width of the edges represents the number of significant LRIs between the two types of cells in mouse lungs treated with DOX+LDN, subtracting the number of LRIs at week 0. (D) The log2 transformed number of trans-ligands (ligand and receptor expressed in different types of cells) of each cell type in the cell–cell communication network in panel A, indicating that macrophages function as central mediators in mouse lungs treated with DOX+LDN. (E) Heatmap showing each KEGG pathway contained which genes. Those pathways and genes were related to Figure 5D. (F) Hierarchical clustering of the expression levels of macrophage-specific chemokines in alveolar macrophages of mouse lungs under indicated treatments. The treatment groups are indicated at the top; the cell types are indicated at the bottom. (G) Heatmap of the average expression of ATM and PTM associated genes in alveolar macrophages in the indicated treatment group. Each column represents a single cell, and each row represents one gene. The expression levels were standardized by taking the z-score within each row. (H) Box plot of ATM/PTM scores (calculated based on marker genes from Li et. al., see STAR Methods in the method section for details) of alveolar macrophages in mouse lungs with indicated treatment.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.7 Inhibition of the BMP2/4-ACVR1 axis reverses macrophage polarization, related to Figure 5 (A) The expression of representative marker genes superimposed on the t-SNE plots. Each color indicates a subtype of alveolar macrophages. (B) Heatmap showing the expression pattern of the top 10 marker genes for each subtype of alveolar macrophages, determined using Seurat. (C) Depiction of a network for ligand-receptor interactions (LRIs) among different cell types in mouse lungs treated with DOX+LDN. Each node represents a cell type. The size of each node shows the number of LRIs occurring for each given cell type. The width of the edges represents the number of significant LRIs between the two types of cells in mouse lungs treated with DOX+LDN, subtracting the number of LRIs at week 0. (D) The log2 transformed number of trans-ligands (ligand and receptor expressed in different types of cells) of each cell type in the cell–cell communication network in panel A, indicating that macrophages function as central mediators in mouse lungs treated with DOX+LDN. (E) Heatmap showing each KEGG pathway contained which genes. Those pathways and genes were related to Figure 5D. (F) Hierarchical clustering of the expression levels of macrophage-specific chemokines in alveolar macrophages of mouse lungs under indicated treatments. The treatment groups are indicated at the top; the cell types are indicated at the bottom. (G) Heatmap of the average expression of ATM and PTM associated genes in alveolar macrophages in the indicated treatment group. Each column represents a single cell, and each row represents one gene. The expression levels were standardized by taking the z-score within each row. (H) Box plot of ATM/PTM scores (calculated based on marker genes from Li et. al., see STAR Methods in the method section for details) of alveolar macrophages in mouse lungs with indicated treatment.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.4. Macrophage-derived chemokine interactions shift toward Treg recruitment during tumorigenesis, related to Figure 3. (A) Enrichment analysis between Mac_a1 and Mac_a2. (B) Heatmap showing each KEGG pathway contained which genes. Those pathways and genes were related to Figure 3A. (C) Expression levels of selected chemokines and cytokines in the different subtypes of monocytes and macrophages in t-SNE projection. Each color indicates one cell subtype. (D) The expression levels of Ccl17 and Ccl22 in macrophages were assessed via bulk RNA-seq analysis at each time point (n=3 for all time points). (E) Flow cytometry analysis of Treg cells from mouse lung tumors induced with doxycycline (2mg/ml) for 0, 1, 2, and 4 weeks. Flow cytometry plots (left) and frequencies (right) of Treg cells (CD45+CD3+CD4+Foxp3+) at the indicated time points. Each dot represents an individual mouse. Consistent with the single-cell analysis, recruitment of Treg cells was significantly increased after 4 weeks of doxycycline induction. (F) Barplot of flow cytometric analysis of Treg cells (CD45⁺CD3⁺CD4⁺Foxp3⁺) in mouse lung tumors at different doxycycline induction time points: no induction (0 week), 4 weeks, and 8 weeks. Each dot represents an individual mouse. (G) Box plot of Th1/Th2 scores of Mac_d cells at each time point. (H) Heatmap of average expression of Th1 and Th2 like signature genes in Mac_d cells at each time point. Each column represents one single cell and each row represents one gene. The expression levels were standardized by taking the z-score within each row. The top bar indicates the time points. The left bar denotes the Th1/Th2 marker genes. (I) Box plot of T cell cytotoxity (Left), activation (Middle) and exhaustation (Right) scores of CD8+ T cells at each time point. (J) Parallel plot of Transcription factor and target relationships. Targets were Th1 like markers whose expression changed significantly between Mac_b and Mac_c.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.4. Macrophage-derived chemokine interactions shift toward Treg recruitment during tumorigenesis, related to Figure 3. (A) Enrichment analysis between Mac_a1 and Mac_a2. (B) Heatmap showing each KEGG pathway contained which genes. Those pathways and genes were related to Figure 3A. (C) Expression levels of selected chemokines and cytokines in the different subtypes of monocytes and macrophages in t-SNE projection. Each color indicates one cell subtype. (D) The expression levels of Ccl17 and Ccl22 in macrophages were assessed via bulk RNA-seq analysis at each time point (n=3 for all time points). (E) Flow cytometry analysis of Treg cells from mouse lung tumors induced with doxycycline (2mg/ml) for 0, 1, 2, and 4 weeks. Flow cytometry plots (left) and frequencies (right) of Treg cells (CD45+CD3+CD4+Foxp3+) at the indicated time points. Each dot represents an individual mouse. Consistent with the single-cell analysis, recruitment of Treg cells was significantly increased after 4 weeks of doxycycline induction. (F) Barplot of flow cytometric analysis of Treg cells (CD45⁺CD3⁺CD4⁺Foxp3⁺) in mouse lung tumors at different doxycycline induction time points: no induction (0 week), 4 weeks, and 8 weeks. Each dot represents an individual mouse. (G) Box plot of Th1/Th2 scores of Mac_d cells at each time point. (H) Heatmap of average expression of Th1 and Th2 like signature genes in Mac_d cells at each time point. Each column represents one single cell and each row represents one gene. The expression levels were standardized by taking the z-score within each row. The top bar indicates the time points. The left bar denotes the Th1/Th2 marker genes. (I) Box plot of T cell cytotoxity (Left), activation (Middle) and exhaustation (Right) scores of CD8+ T cells at each time point. (J) Parallel plot of Transcription factor and target relationships. Targets were Th1 like markers whose expression changed significantly between Mac_b and Mac_c.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.6. BMP2 and BMP4 upregulation correlates with poor prognosis, related to Figure 4. (A) Immunofluorescence staining for CD68 (yellow) along with DNA visualized by DAPI staining. The upper four represent adjacent non-cancerous tissues, while the lower four are the corresponding cancerous tissues. Scale bar :50um. (B) Quantification of CD68⁺ cells (macrophages) in equal-area regions of matched tumor and adjacent non-tumor tissues using immunofluorescence imaging. Each pair of data points represents tumor and adjacent tissue from the same individual, and different pairs represent different individuals. The number of macrophages was significantly higher in tumor regions compared to adjacent tissues (P < 0.01, paired t test). (C, D) Box plot quantifying the proportions of CD8+ T cells in nonEGFR and EGFR-mutant patients from scRNA-seq dataset (C), and TCGA database (D), highlighting an increase in the proportion of CD8+ T cells in EGFR-mutant NSCLC patients. (E) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low ACVR1 gene expression in the LUAD TCGA database. The Kaplan–Meier curves were used to visualize and compare the OS of the low-risk (blue) versus high-risk (red) group in EGFR-mutant patients (left), in non-EGFR–mutant patients (medium), and all EGFR-mutant patients(right) highlighting ACVR1 gene expression is correlated with the OS of EGFR-mutant patients but not non-EGFR–mutant patients. (F) Proportion of ACVR1⁺CD68⁺ cells among total ACVR1⁺ cells in paired normal and tumor tissues. Each line represents an individual sample. (G) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low macrophage polarization signatures in the LUAD database. (Left) Higher expression of the M1-associated ATM signature was significantly associated with improved overall survival (log-rank p = 0.021). (Right) Expression of the M2-associated PTM signature showed no significant association with survival (log-rank p = 0.42). (H) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low ACVR1 gene expression in the LUAD TCGA database. The Kaplan–Meier curves were used to visualize and compare the OS of the low-risk (blue) versus high-risk (red) group in KRAS-mutant patients (left) and in non-EGFR–mutant patients (right). (I) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low ACVR1 gene expression in other cancer types of TCGA database. The Kaplan–Meier curves were used to visualize and compare the OS of the low-risk versus high-risk group in indicated cancer types. (J) ACVR1 expressed Macrophage is enriched in non-responders. Both mean expression of ACVR1 and ratio of ACVR1 expressed macrophages were higher in non-responders. Public Data were used27–32. (K) Heatmap showing correlation between cytotoxicity T cell scores and ACVR1 in indicated cancer types assessed by TIDE33.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.6. BMP2 and BMP4 upregulation correlates with poor prognosis, related to Figure 4. (A) Immunofluorescence staining for CD68 (yellow) along with DNA visualized by DAPI staining. The upper four represent adjacent non-cancerous tissues, while the lower four are the corresponding cancerous tissues. Scale bar :50um. (B) Quantification of CD68⁺ cells (macrophages) in equal-area regions of matched tumor and adjacent non-tumor tissues using immunofluorescence imaging. Each pair of data points represents tumor and adjacent tissue from the same individual, and different pairs represent different individuals. The number of macrophages was significantly higher in tumor regions compared to adjacent tissues (P < 0.01, paired t test). (C, D) Box plot quantifying the proportions of CD8+ T cells in nonEGFR and EGFR-mutant patients from scRNA-seq dataset (C), and TCGA database (D), highlighting an increase in the proportion of CD8+ T cells in EGFR-mutant NSCLC patients. (E) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low ACVR1 gene expression in the LUAD TCGA database. The Kaplan–Meier curves were used to visualize and compare the OS of the low-risk (blue) versus high-risk (red) group in EGFR-mutant patients (left), in non-EGFR–mutant patients (medium), and all EGFR-mutant patients(right) highlighting ACVR1 gene expression is correlated with the OS of EGFR-mutant patients but not non-EGFR–mutant patients. (F) Proportion of ACVR1⁺CD68⁺ cells among total ACVR1⁺ cells in paired normal and tumor tissues. Each line represents an individual sample. (G) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low macrophage polarization signatures in the LUAD database. (Left) Higher expression of the M1-associated ATM signature was significantly associated with improved overall survival (log-rank p = 0.021). (Right) Expression of the M2-associated PTM signature showed no significant association with survival (log-rank p = 0.42). (H) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low ACVR1 gene expression in the LUAD TCGA database. The Kaplan–Meier curves were used to visualize and compare the OS of the low-risk (blue) versus high-risk (red) group in KRAS-mutant patients (left) and in non-EGFR–mutant patients (right). (I) Kaplan–Meier plots for overall survival (OS), with log-rank tests between cases with high and low ACVR1 gene expression in other cancer types of TCGA database. The Kaplan–Meier curves were used to visualize and compare the OS of the low-risk versus high-risk group in indicated cancer types. (J) ACVR1 expressed Macrophage is enriched in non-responders. Both mean expression of ACVR1 and ratio of ACVR1 expressed macrophages were higher in non-responders. Public Data were used27–32. (K) Heatmap showing correlation between cytotoxicity T cell scores and ACVR1 in indicated cancer types assessed by TIDE33.
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Table 1: Primer sequences for qRT-PCR
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Table 1: Primer sequences for qRT-PCR
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Table 2: The information of obtained cells
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Table 2: The information of obtained cells
- Open Access
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.8. Inhibition of the BMP2/4-ACVR1 axis transforms the ‘cold’ tumor to a ‘hot’ state, related to Figure 6 (A) H&E strain images of lung sections derived from mice under indicated treatments showing that DMH1 treatment significantly reduced the tumor burden in the mouse lung. Scale bar :50um. (B) Box plot showing the proportions of Treg, T cells, neutrophils and monocytes (from left to right) at 0w, 4 weeks induction and 4 weeks induction with DMH1. (C) Bar plot quantifying the proportions of various types of non-immune cells at each time point, highlighting a rapid expansion of cancer cells. (D) Bar plot showing changes in CD8⁺ T cells. Left: Percentage of CD8⁺ T cells among total CD45⁺ immune cells in lung tissue at baseline (0W), after 4 weeks of tumor induction without LDN treatment (4W), and after 4 weeks of tumor induction with LDN treatment initiated at week 2(4W+LDN). Right: Absolute number of CD8⁺ T cells per mg of lung tissue. LDN was administered via intraperitoneal injection starting from week 2 of tumor induction. (E) Barplot of Median fluorescence intensity (MFI) of IFNγ expression in CD8⁺ T cells. (F) Weight of mice treated with the two different inhibitors (n=5). Showing no significant weight loss over the course of the treatment. (G) Flow cytometry plots of early apoptosis cells of PC9 cell line (PI-AnnexinV+) and apoptosis cells (PI+AnnexinV+) treated by gefitinib, LDN, and DMH1 for 24 hours. (H) Frequencies (top) of early apoptosis cells of PC9 cell line (PI-AnnexinV+) and apoptosis cells (PI+AnnexinV+) treated by gefitinib, LDN, and DMH1 for 24 hours. (I) The survival rate, as measured by CCK 8, of PC9 cells in indicated groups. (J) Tumor volume in mice bearing PC9 cells under indicated treatments. (K) H&E strain images of lung sections derived from mice under indicated treatments showing that the treatment could still significantly reduced the tumor burden in the mouse lung even in advanced tumor. Scale bar :50um.
- 19 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Protumor Macrophage Polarization Mediated by BMP2/4–ACVR1 Signaling Orchestrates an Immunosuppressive Microenvironment during Tumor Initiation
Extended Data Fig.8. Inhibition of the BMP2/4-ACVR1 axis transforms the ‘cold’ tumor to a ‘hot’ state, related to Figure 6 (A) H&E strain images of lung sections derived from mice under indicated treatments showing that DMH1 treatment significantly reduced the tumor burden in the mouse lung. Scale bar :50um. (B) Box plot showing the proportions of Treg, T cells, neutrophils and monocytes (from left to right) at 0w, 4 weeks induction and 4 weeks induction with DMH1. (C) Bar plot quantifying the proportions of various types of non-immune cells at each time point, highlighting a rapid expansion of cancer cells. (D) Bar plot showing changes in CD8⁺ T cells. Left: Percentage of CD8⁺ T cells among total CD45⁺ immune cells in lung tissue at baseline (0W), after 4 weeks of tumor induction without LDN treatment (4W), and after 4 weeks of tumor induction with LDN treatment initiated at week 2(4W+LDN). Right: Absolute number of CD8⁺ T cells per mg of lung tissue. LDN was administered via intraperitoneal injection starting from week 2 of tumor induction. (E) Barplot of Median fluorescence intensity (MFI) of IFNγ expression in CD8⁺ T cells. (F) Weight of mice treated with the two different inhibitors (n=5). Showing no significant weight loss over the course of the treatment. (G) Flow cytometry plots of early apoptosis cells of PC9 cell line (PI-AnnexinV+) and apoptosis cells (PI+AnnexinV+) treated by gefitinib, LDN, and DMH1 for 24 hours. (H) Frequencies (top) of early apoptosis cells of PC9 cell line (PI-AnnexinV+) and apoptosis cells (PI+AnnexinV+) treated by gefitinib, LDN, and DMH1 for 24 hours. (I) The survival rate, as measured by CCK 8, of PC9 cells in indicated groups. (J) Tumor volume in mice bearing PC9 cells under indicated treatments. (K) H&E strain images of lung sections derived from mice under indicated treatments showing that the treatment could still significantly reduced the tumor burden in the mouse lung even in advanced tumor. Scale bar :50um.